Our Speakers
Specificities of the Greek Healthcare System
The healthcare system in Greece combines universal public services and a vibrant private sector, providing diverse options to citizens and residents. While it ensures broad access to care through ESY and EOPYY insurance, it faces challenges such as lack of resources, long waiting times, and inequalities in access to services. Despite these limitations, the system remains an important safety net, with an orientation towards improvement through progressive reforms and investments.
Kyriakos Souliotis, Professor of Health Policy, Dean of the School of Social & Political Sciences, Director, Laboratory for the Evaluation of Health Policies, Technologies & Behaviors, University of Peloponnese, Corinth, Greece
Sales evolution of Pharma Market in Greece
Pharmaceutical & Consumer Health Trends in Greek Pharma Market
Offline and Online channels analysis
Other market milestones
Konstantinos Georgiou, Engagement Manager – Head of Consulting, IQVIA Greece
Mastering a License Deal
Licensing agreements seem to be easy and straight forward. However there are traps to be considered. .Precise business planning is key, being the basis for the right rationale to calculate the license fees. What do we license in/out in the end? Does it give the anticipated scope to the licensee, does it still allow the licensor the freedom to operate?
Manfred Stadler, Partner, VINC advisory
Key success factors for pharmaceutical companies in Germany, and how BPI can support”
Germany is currently the 4th largest pharmaceutical market in the world, supported by a statutory healthcare system that provides services to over 80 million citizens.
The country offers rapid market access and reimbursement for innovative medicines, making it an attractive destination for pharmaceutical companies.
The BPI, with over 70 years of experience, is the only national association representing the ENTIRE pharmaceutical industry portfolio, encompassing around 230 member companies from large multinationals to SMEs and startups.
BPI provides members with valuable services, including analyses, information and OPERATIONAL SUPPORT FOR ITS MEMBERS on current topics, and facilitates discussions through over 50 working groups.
The organization plays a crucial role in advocating for industry interests with policymakers at various governmental levels.
Dr. med. Kai Joachimsen, MBA, Bundesverband der Pharmazeutischen Industrie e.V., CEO
axunio – empowering the overlooked patient
In this presentation, we would like to present our company. We, axunio Pharma GmbH, sell and promote pharmaceuticals in our home market Germany, as well as in the UK, Scandinavia, and the Netherlands. We launched our first product in 2016 and have accomplished major milestones ever since. Our mission is to identify minority needs, which tend to be overlooked. Therefore, we are continuously looking for niche and/or value-added products to in-license or acquire (including the brand). The latter applies to UK in particular, as we are planning to open up our own office there. We believe in targeted and outside-the-box marketing approaches that are built on thorough market analysis and close relationships with KOL from the respective medical areas.
Julia Von Horsten, Business Development Manager, axunio Pharma GmbH
Ina Kühnemund, Managing Director, axunio Pharma GmbH
Farmasyn : “We put the patient first”
FarmaSyn S.A. is a company committed to delivering innovative, accessible, and reliable therapeutic solutions. Established in 1994, FarmaSyn has grown through strategic alliances with international leaders, including Cheplapharm, Engelhard, Sandoz and IBSA. Certified to the most exacting European standards, FarmaSyn’s prioritization of quality and patient trust has established it as a dependable partner for healthcare providers and patients in Greece.
Nikolaos Makrigiannis, Business Development Manager, FarmaSyn SA
Vianex S.A.: Proudful Past - Faithful Future
With 100 years of history in the pharmaceutical industry and a commitment to People, the VIANEX Group has strongly connected its presence with the economic and business evolution of modern Greece.
Our company’s exceptionally high quality and excellent organizational infrastructure are the reasons why we enjoy successful and long-lasting partnerships with major international pharmaceutical companies, for the promotion and distribution of their products in the Greek territory, through license agreements, in the area of Rx & OTC/FS.
Furthermore, VIANEX S.A. has 4 fully specialized manufacturing plants thus exporting and contract manufacturing represent one of our key objectives. Today, it represents the largest production force in the Greek pharmaceutical industry. The annual production volume is over 121 million units. The company enjoys more than 100 international partnerships, exports to 114 countries with a workforce of over 1,300 employees.
Evi Vallianatou | Head of Corporate Developmen, Vianex sa
Reviving & upgrading old molecules: Challenges & Opportunities
The speaker will address the main challenges faced when upgrading or developing the registration dossier for an old molecule. He will then elaborate on the opportunities which some of these old molecules present and the partners Medochemie seeks to commercialise such molecules.
Andreas Loizou, Group Business Development Director,Medochemie Ltd.
AI in Pharma: a transformative Pilot in Market Access
This session will provide you with valuable insights into how AI can transform your operations today and prepare you for tomorrow’s challenges in critical fields like regulatory affairs and quality management.
You will also discover CLEVAIR-HTA, our advanced AI solution designed to support your market access needs while paving the way for broader integration tailored to the unique needs of small and medium-sized pharmaceutical companies.
Henry Jonckheere and Marc Czarka, Administrators MAEVH sas
Bio-Pharma CEO Survey and Report Future Optimism Score
VINC’s yearly Bio-Pharma CEO Report, that is being prepared in co-operation with EuropharmSMC, provides exclusive industry insights, which support top management in strategic decision-making as well as in identifying growth and investment opportunities. It provides insights on strategic topics from SMEs for SMEs in pharma and bio-pharma (incl. service providers) – a report that is unparalleled.
VINC will present the highlights of the Future Optimism Score 2025 and will also outline what will be new in the upcoming report.
Highlights of the report:
• Market Sentiment and Outlook: Industry insights and perspectives of European Bio-Pharma CEOs
• Investment Trends: Analysis of key investment priorities and financial outlooks
• Strategic Partnerships: Overview of collaboration strategies driving growth and innovation
New this year: For the first time, business leaders will be able to benchmark their personal data against industry peers.
Thomas Kern, Managing Director, VINC Healthcare Advisory and ISP HEALTHCARE
MITELOS: Building Partnerships in Healthcare Innovation
Founded in 2013 in Barcelona, Mitelos develops, registers, and manufactures healthcare products with a focus on ENT. Present in more than 20 countries, with a remarkable track record, we work exclusively B2B, partnering with companies that excel in promoting and selling our products. At Mitelos, we don’t just create products – we forge long term partnerships. Our model designed to support our partners at every step, from regulatory clearance and market analysis to achieve the best market positioning and follow-up during the whole partnership. Indeed, since inception, Mitelos has helped its partners enlarge ENT and /or healthcare portfolio, contributing to their success while improving patient care worldwide.
Sonia Barrón, Director, Corporate Development, Mitelos Bioscience sl
European union drug agency’s call to action. How nasal naloxone becomes an important part of the response.
At the end of 2024, EU’s drug agency published a call to action among the member states, as new synthetic opioids are taking over the illicit drug supply with the Taliban opium ban in Afghanistan, disrupting the heroin supply. The potent synthetic opioids increase the risk of intoxication, overdose, and possible outbreaks across Europe. The member states are acting to be prepared, and one of the more important tools is to ensure an efficient take-home naloxone program. Ventizolve is today available in 7 countries, and we are looking for partners to make it available across Europe.
Nina Kristin Måsvær , Head of Marketing and Business development, dne Pharma as
KS Pharma: The power of connection for innovative solutions
At KS Pharma, we don’t just offer services—we build long-term connections.
In an industry where availability and global reach make the difference, we’ve spent years crafting a trusted network that ensures seamless collaboration across borders.
Our strength lies in always being reachable, adapting swiftly, and delivering solutions that go beyond the conventional.
Join us to discover how KS Pharma is redefining pharma partnerships—where responsiveness meets global impact.
Sacha Masson, General Manager, KS Pharma
What’s Stopping You? Turning Global Compliance Hurdles into Market Opportunities — Your 5-Year Plan
This session challenges common misconceptions around global regulatory expansion and provides a clear, phased roadmap to help European pharmaceutical companies turn compliance challenges into international growth opportunities. It will highlight key markets, share insights from real-world case studies, and offer practical steps for building a compliance-led strategy for global success.
Objectives:
· Identify common barriers to global expansion
· Present a 5-year phased plan for international compliance and growth
· Share success stories and lessons learned
· Position compliance as a strategic driver for market entry
Dr Graeme Ladds – CEO, PharSafer®